OptumRx GLP-1 coverage: formulary tiers, PA criteria, and 2026 UM rules

OptumRx — the pharmacy benefit manager arm of UnitedHealth Group's Optum division — manages formulary design, prior authorization (PA), step therapy, and specialty pharmacy routing for tens of millions of commercial, Medicare Part D, Medicaid, and government-program members. In 2025–2026, OptumRx expanded its GLP-1 utilization management toolkit with new cardiometabolic PA options, tightened quantity limits, and adjusted formulary exclusions that affect which GLP-1 drugs patients can access and at what cost.

This guide maps how OptumRx covers GLP-1 receptor agonists across its formulary lines, details PA and step therapy criteria for each indication, explains the 2026 utilization management changes, and provides a plan-by-formulary breakdown. It is independent information and not medical advice or reimbursement guidance for a specific patient or plan.

Quick answer

PA = prior authorization. QL = quantity limit. Tier placement varies by employer or plan election.

OptumRx formulary lines explained

OptumRx operates three main formularies for different market segments:

Premium Formulary

The Premium Formulary is the most widely used commercial formulary. It uses a tiered copay structure (Tier 1 = generics, Tier 2 = preferred brands, Tier 3 = non-preferred brands) and includes GLP-1s for both T2D and weight-loss indications on most plans. Key points:

• Ozempic, Mounjaro, Rybelsus, and Trulicity are Tier 2 with PA and quantity limits.
• Wegovy, Zepbound, and Saxenda are Tier 2 with PA, QL, and often step therapy.
• Some premium formularies exclude Zepbound vials while covering single-dose pens.
• The July 2025 formulary update moved Contrave to the exclusion list for obesity, directing members toward phentermine, Qsymia, Saxenda, Wegovy, or Zepbound.

Select Standard Formulary

The Select Standard Formulary is a cost-management-focused formulary used by plans seeking tighter formulary control. GLP-1 placement is similar to the Premium Formulary, but:

• More aggressive exclusions may apply (e.g., Zepbound vials excluded; only auto-injector pens covered).
• Step therapy requirements may be broader, requiring trial of multiple preferred alternatives.
• Some employer plans on the Select Standard Formulary exclude weight-loss GLP-1s entirely.

Comprehensive (Medicare) Formulary

For Medicare Part D and retiree plans, the Comprehensive Formulary places weight-loss GLP-1s at Tier 3 with PA and QL. Under CMS rules, Medicare Part D generally does not cover drugs prescribed for weight loss. However:

• The CMS $50/month demonstration program launching July 1, 2026, will allow qualifying Medicare beneficiaries to access select GLP-1 drugs for obesity treatment.
• Diabetes-indicated GLP-1s (Ozempic, Mounjaro, Rybelsus, Trulicity) remain covered under Part D for T2D.
• Wegovy for MASH or cardiovascular risk reduction may be covered under Part D on a case-by-case basis with supporting documentation.

2026 utilization management changes

In its September 2025 Pharmacy Passages announcement, OptumRx outlined significant utilization management (UM) changes effective January 1, 2026:

Non-diabetes GLP-1 PA options expanded

OptumRx expanded its PA options for non-diabetes GLP-1 prescriptions (weight loss, MASH, OSA, cardiovascular risk reduction) with a new cardiometabolic PA pathway in addition to the existing standard, label-based, and risk-stratified options. This gives plan sponsors four distinct PA frameworks:

Plan sponsors select which PA option applies to their members. This means two patients on different OptumRx plans can face different PA criteria for the same drug.

Formulary exclusions and tier changes

The January 2026 update includes:

• 10 drugs excluded from the Select Formulary and 11 from the Premium Formulary (not all GLP-1 related).
• Wegovy and Zepbound remain on formulary but with tightened PA criteria on many plans.
• OneTouch meters and test strips excluded from the Premium Formulary effective January 1, 2026; on the Select Standard Formulary, OneTouch products were uptiered to Tier 3 with step therapy added (requiring trial of Contour, FreeStyle, or Precision products first).

Quantity limits

OptumRx applies quantity limits (QL) to all GLP-1s:

Prior authorization criteria by indication

Type 2 diabetes

For Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza, and other diabetes-indicated GLP-1s, OptumRx requires:

1. Confirmed T2D diagnosis with documented laboratory evidence:

   • HbA1c ≥ 6.5%, OR
   • Fasting plasma glucose ≥ 126 mg/dL, OR
   • 2-hour plasma glucose ≥ 200 mg/dL during OGTT, OR
   • Random plasma glucose ≥ 200 mg/dL with classic symptoms of hyperglycemia

2. Step therapy may apply — some plans require documented trial of metformin before GLP-1 approval.

3. No dual GLP-1 therapy — patient should not be on multiple GLP-1 receptor agonists simultaneously.

4. Prescriber attestation — medical records with relevant diagnosis information must accompany the PA submission.

Chronic weight management (Wegovy, Zepbound, Saxenda)

For plans that cover weight-loss GLP-1s, OptumRx PA criteria typically require:

1. BMI documentation (measured in clinic, not self-reported):

   • Adults: BMI ≥ 30 kg/m², OR BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, coronary heart disease, MASH/NASH, obstructive sleep apnea)
   • Pediatric patients: BMI ≥ 95th percentile standardized for age and sex

2. Lifestyle modification:

   • Patient is participating in a supervised comprehensive weight management program that includes behavioral modification, reduced-calorie diet, and increased physical activity

3. No dual GLP-1 therapy — Wegovy, Zepbound, or Saxenda should not be combined with other GLP-1 receptor agonists (Ozempic, Mounjaro, Rybelsus, Trulicity, Soliqua, Xultophy, etc.)

4. Step therapy for Zepbound — on some plans, Zepbound requires prior trial of preferred GLP-1 weight-loss products (which may include Saxenda and/or Wegovy depending on formulary) and/or oral weight-management medications, unless a valid medical exception exists (inadequate treatment response, intolerance, or contraindication). Specific step therapy sequences vary by plan and formulary election.

5. Reauthorization — continued coverage requires documented weight loss of ≥ 5% of baseline body weight, verified by medical records.

MASH/NASH indication

For Wegovy prescribed for metabolic dysfunction-associated steatohepatitis (MASH), OptumRx requires:

1. Disease confirmed as fibrosis stage F2 or F3 by one of:

   • FibroScan
   • Fibrosis-4 index (FIB-4)
   • Magnetic Resonance Elastography (MRE)
   • Liver biopsy

2. Prescribed by or in consultation with a gastroenterologist or hepatologist.

Obstructive sleep apnea (Zepbound only)

For Zepbound prescribed for moderate-to-severe OSA:

1. BMI ≥ 30 kg/m²
2. Sleep study confirming AHI or REI > 15 events/hour
3. Prior trial or contraindication of CPAP/BiPAP
4. Prescribed by or in consultation with a sleep specialist
5. Patient counseled on positional therapy and avoidance of alcohol/sedatives

Specialty pharmacy routing

OptumRx typically routes GLP-1 prescriptions through:

• Optum Specialty Pharmacy (mail-order) — for ongoing maintenance fills
• Retail specialty pharmacies — for initial fills and patients who prefer in-person pickup
• Limited distribution networks — for some GLP-1 products, OptumRx may restrict fills to specific specialty pharmacies

Patients should verify the dispensing pharmacy is in the OptumRx network to avoid higher out-of-pocket costs. The OptumRx member portal and phone line can confirm network pharmacies.

How OptumRx relates to UHC, UMR, and employer plans

OptumRx is the PBM that manages pharmacy benefits for:

This means an OptumRx GLP-1 denial on a UMR plan may be governed by different appeal rules than a denial on a fully insured UHC plan, even though OptumRx processes both.

Common denial reasons and appeal steps

Common denials

• Weight-loss GLP-1 excluded — the employer or plan sponsor did not elect coverage.
• BMI below plan threshold — some plans use stricter thresholds (BMI ≥ 35 or ≥ 40) than the OptumRx standard.
• Missing lifestyle modification records — no documentation of supervised weight management program.
• Step therapy not completed — prior trials of preferred alternatives not documented.
• Stale BMI or labs — measurements older than 90 days may be rejected.
• Insufficient weight loss at reauthorization — < 5% body weight loss documented.
• Missing prescriber specialty consultation — for MASH (GI/hepatology) or OSA (sleep specialist), the consultation requirement was not met.

Appeal workflow

1. Prescriber submits PA with all required documentation (BMI, labs, lifestyle records, diagnosis codes).
2. If denied: Request the specific denial reason and PA criteria in writing.
3. First-level appeal: Submit written appeal with letter of medical necessity and supporting records.
4. Peer-to-peer review: Prescriber requests direct conversation with OptumRx medical reviewer.
5. Second-level appeal / external review: Available under ACA and state insurance regulations.
6. Plan sponsor escalation: For self-funded plans, the employer benefits team may authorize an exception.

Key contacts

• OptumRx Member Services: Phone number on the back of your insurance card
• OptumRx Provider Formulary Updates: business.optum.com/formulary-updates
• Optum Specialty Pharmacy: optumrx.com
• UnitedHealthcare Provider Portal: uhcprovider.com

Sources

• OptumRx 2026 Premium Formulary, effective January 1, 2026. Optum Rx, Inc. Available at: contenthub-aem.optumrx.com
• OptumRx 2026 Select Standard Formulary, effective January 1, 2026. Optum Rx, Inc. Available at: contenthub-aem.optumrx.com
• OptumRx 2026 Comprehensive (Non-Medicare) Formulary. Available at: contenthub-aem.optumrx.com
• OptumRx Prior Authorization Form: GLP-1 Agonists (TennCare), revision August 2025. Available at: contenthub-aem.optumrx.com
• UnitedHealthcare Pharmacy: Prior Authorization/Notification — Plans with Weight Loss/Appetite Suppression Medication Coverage, Program 2026 P 1114-20. Available at: uhcprovider.com
• OptumRx Formulary Update, Pharmacy Passages, September 2025. Available at: business.optum.com
• OptumRx Formulary & UM Updates for Providers, 2026. Available at: business.optum.com
• PSG Consulting: "2025 Formulary Changes: OptumRx." Available at: psgconsults.com
• ASGE: "Medicare GLP-1 Program Begins July 1," May 14, 2026. Available at: asge.org
• Centers for Medicare & Medicaid Services (CMS): Medicare Part D GLP-1 Drug Coverage and Demonstration Program, 2026. Available at: https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation